Closely held PharmaJet has announced that it has signed a distribution agreement with ATR, an affiliate to closely held EVA Pharma. The agreement, signed in Frankfurt at the CPHI meeting on October 30, 2025, includes provisions for Tropic distribution, technology transfer, and manufacturing.
The aim of the collaboration is to increase needle-free access within Egypt and regionally while broadening Egypt’s manufacturing capabilities. PharmaJet’s Tropis intradermal needle-free delivery offers several strategic advantages for Egypt including substantial polio immunization cost savings, reduced vaccine hesitancy, increased coverage, and the potential for medical technology regional manufacturing. The signing follows the July 2025 Memo of Understanding (MOU) that was signed between PharmaJet, Egypt’s Unified Procurement Agency (UPA) and EVA Pharma, which outlined plans for how UPA could incorporate Tropis into its portfolio.
The introduction of Tropis into immunization programs supports Egypt’s 1000 Golden Days initiative, which was launched to support the health and development of families during the critical period from conception to a child’s second birthday. The collaboration will enable total immunization cost reduction and improved acceptability of polio vaccinations. Longer-term, the Tropis manufacturing and other needle-free product development initiatives may expand the benefits to vaccination against other infectious agents and improved pandemic preparedness.
EVA Pharma is a leading pharmaceutical and medical appliances manufacturing company that has vast experience in manufacturing, registering, marketing, distributing, and promoting pharmaceutical products. “This collaboration puts children first,” said Riad Armanious, CEO of EVA Pharma. “We’re reimagining vaccination through local innovation that improves every child’s experience while empowering healthcare professionals. By localizing manufacturing, we expand access and use existing budgets to reach many more children in Africa sustainably.”
Paul LaBarre, SVP of business development for PharmaJet, commented, “We are proud to collaborate with ATR and EVA Pharma to localize needle-free manufacturing and delivery. This partnership represents a strategic step forward for PharmaJet in the Middle East and Northern Africa region. Working with these innovative teams will accelerate integration of needle-free intradermal vaccine delivery into routine immunization programs in Egypt and beyond.”
